ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.
about
The LDL Receptor-Related Protein 1: At the Crossroads of Lipoprotein Metabolism and Insulin SignalingDesign and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.Key differences between apoC-III regulation and expression in intestine and liver.Triglyceride Treatment in the Age of Cholesterol Reduction.Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability Is an Independent Determinant of Carotid Intima-Media Thickness in Patients With Type 2 Diabetes.Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes.Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL.Lipoprotein lipase activity and interactions studied in human plasma by isothermal titration calorimetry.New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.γ-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor.Brown adipose tissue derived ANGPTL4 controls glucose and lipid metabolism and regulates thermogenesis.Absence of ANGPTL4 in adipose tissue improves glucose tolerance and attenuates atherogenesis.Increased inflammation, endoplasmic reticulum stress and oxidative stress in endothelial and macrophage cells exacerbate atherosclerosis in ApoCIII transgenic mice
P2860
Q33726334-3FE21D41-8FDD-42A0-AC11-0A06FD4176E1Q33730396-1F5DAC6A-4261-461E-AEB0-B278F1C71190Q34551430-2EFA7A74-4F49-498D-B7EC-254CAEF0D94DQ38616263-6CCE7794-E9E9-4B32-B44A-DA22B62B58D3Q38664013-FC7804BF-41F0-4E31-B62C-992F83699283Q38932760-48993B00-6342-4C8A-AE0B-02F0FC6EF7D2Q40214593-39F150AF-4F1B-4490-9C10-05752F838E33Q42075891-5A58F0DF-68AC-448A-A20E-FE234FE12ED5Q42400268-99D5572E-C410-471C-B3E6-60C090781C0EQ46300109-805F58AA-60D3-46C6-9211-8DA15BBB1424Q47145731-184D0022-C3BC-4FFB-A1E3-2C949F820D95Q50044216-827EB791-1EA3-44B3-9C6F-2ED4FED74A85Q51172839-739D7DCA-F03F-435C-836C-FE51A30C59E4Q51735096-6BF7FABB-30E1-4A41-B993-2F8C602ED6C0Q52600970-E15E638F-9D9C-416E-BA49-90DF32D7A43EQ52644015-7A8052D0-56D5-4F8C-8115-675B4811A6D5Q58732897-4659AAC8-0886-4658-B3FF-1CB705A1468E
P2860
ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
ApoC-III inhibits clearance of ...... through LDL family receptors.
@en
ApoC-III inhibits clearance of ...... through LDL family receptors.
@nl
type
label
ApoC-III inhibits clearance of ...... through LDL family receptors.
@en
ApoC-III inhibits clearance of ...... through LDL family receptors.
@nl
prefLabel
ApoC-III inhibits clearance of ...... through LDL family receptors.
@en
ApoC-III inhibits clearance of ...... through LDL family receptors.
@nl
P2093
P2860
P356
P1476
ApoC-III inhibits clearance of ...... s through LDL family receptors
@en
P2093
Adam E Mullick
Bastian Ramms
Debapriya Basu
Ira J Goldberg
Jeffrey D Esko
Jon C Gonzales
Joseph L Witztum
Mark J Graham
Ni-Huiping Son
P2860
P304
P356
10.1172/JCI86610
P407
P577
2016-07-11T00:00:00Z